Acadian Asset Management LLC Acquires 631,794 Shares of Emergent Biosolutions Inc. $EBS

Key Points

• Acadian Asset Management LLC increased its stake in Emergent Biosolutions by 313.5% in Q1, acquiring 631,794 shares for a total of 1.54% ownership valued at approximately $4.05 million.
• Emergent Biosolutions reported $0.16 EPS in its latest earnings, surpassing analysts' expectations, but its revenue of $140.90 million was below the consensus estimate of $148.55 million.
• Institutional investors currently own 78.40% of Emergent Biosolutions' stock, highlighting significant interest from large financial entities.

Acadian Asset Management LLC boosted its holdings in Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 313.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 833,316 shares of the biopharmaceutical company's stock after acquiring an additional 631,794 shares during the period. Acadian Asset Management LLC owned 1.54% of Emergent Biosolutions worth $4,048,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Northern Trust Corp increased its position in Emergent Biosolutions by 2.6% during the fourth quarter. Northern Trust Corp now owns 145,889 shares of the biopharmaceutical company's stock worth $1,395,000 after acquiring an additional 3,692 shares during the period. EP Wealth Advisors LLC increased its position in shares of Emergent Biosolutions by 33.1% in the first quarter. EP Wealth Advisors LLC now owns 15,249 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 3,790 shares during the period. Bank of New York Mellon Corp increased its position in shares of Emergent Biosolutions by 40.4% in the first quarter. Bank of New York Mellon Corp now owns 17,003 shares of the biopharmaceutical company's stock worth $83,000 after purchasing an additional 4,894 shares during the period. SBI Securities Co. Ltd. increased its position in shares of Emergent Biosolutions by 95.1% in the first quarter. SBI Securities Co. Ltd. now owns 12,951 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 6,313 shares during the period. Finally, B. Riley Wealth Advisors Inc. increased its position in shares of Emergent Biosolutions by 21.9% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 41,800 shares of the biopharmaceutical company's stock worth $400,000 after purchasing an additional 7,500 shares during the period. Institutional investors own 78.40% of the company's stock.

Emergent Biosolutions Trading Down 1.0%

Shares of EBS stock opened at $8.15 on Monday. The company has a market cap of $434.81 million, a P/E ratio of 3.33 and a beta of 2.04. The stock has a 50 day simple moving average of $7.71 and a two-hundred day simple moving average of $6.44. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.00 and a current ratio of 5.66. Emergent Biosolutions Inc. has a fifty-two week low of $4.02 and a fifty-two week high of $12.73.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.42. Emergent Biosolutions had a return on equity of 24.63% and a net margin of 16.38%.The business had revenue of $140.90 million during the quarter, compared to the consensus estimate of $148.55 million. Research analysts forecast that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Donald W. Degolyer sold 7,844 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $8.65, for a total transaction of $67,850.60. Following the transaction, the director directly owned 137,659 shares of the company's stock, valued at $1,190,750.35. This represents a 5.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kathryn C. Zoon sold 7,086 shares of the company's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $8.87, for a total value of $62,852.82. Following the transaction, the director directly owned 71,799 shares in the company, valued at $636,857.13. The trade was a 8.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wall Street Zen cut Emergent Biosolutions from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, September 3rd. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Emergent Biosolutions currently has a consensus rating of "Buy" and a consensus target price of $13.50.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.